User login
Key clinical point: Patients with psoriatic arthritis (PsA) and obesity had ~50% lower likelihood of achieving minimal disease activity (MDA) or remission within a year of initiating treatment with biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARD).
Major finding: Odds of achieving MDA (adjusted odds ratio [aOR] 0.45; 95% CI 0.24-0.82) and DAPSA-remission (aOR 0.42; 95% CI 0.21-0.85) were lower in the obese vs normal weight group within the first year; similarly, the overweight group had reduced odds of achieving DAPSA-remission (aOR 0.44; 95% CI 0.24-0.79).
Study details: Findings are from an observational cohort study including 774 adult patients with PsA who started their first b/tsDMARD.
Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.
Source: Vallejo-Yague E et al. Minimal disease activity and remission in patients with psoriatic arthritis with elevated body mass index: An observational cohort study in the Swiss Clinical Quality Management cohort. BMJ Open. 2022;12(9):e061474 (Sep 17). Doi: 10.1136/bmjopen-2022-061474
Key clinical point: Patients with psoriatic arthritis (PsA) and obesity had ~50% lower likelihood of achieving minimal disease activity (MDA) or remission within a year of initiating treatment with biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARD).
Major finding: Odds of achieving MDA (adjusted odds ratio [aOR] 0.45; 95% CI 0.24-0.82) and DAPSA-remission (aOR 0.42; 95% CI 0.21-0.85) were lower in the obese vs normal weight group within the first year; similarly, the overweight group had reduced odds of achieving DAPSA-remission (aOR 0.44; 95% CI 0.24-0.79).
Study details: Findings are from an observational cohort study including 774 adult patients with PsA who started their first b/tsDMARD.
Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.
Source: Vallejo-Yague E et al. Minimal disease activity and remission in patients with psoriatic arthritis with elevated body mass index: An observational cohort study in the Swiss Clinical Quality Management cohort. BMJ Open. 2022;12(9):e061474 (Sep 17). Doi: 10.1136/bmjopen-2022-061474
Key clinical point: Patients with psoriatic arthritis (PsA) and obesity had ~50% lower likelihood of achieving minimal disease activity (MDA) or remission within a year of initiating treatment with biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARD).
Major finding: Odds of achieving MDA (adjusted odds ratio [aOR] 0.45; 95% CI 0.24-0.82) and DAPSA-remission (aOR 0.42; 95% CI 0.21-0.85) were lower in the obese vs normal weight group within the first year; similarly, the overweight group had reduced odds of achieving DAPSA-remission (aOR 0.44; 95% CI 0.24-0.79).
Study details: Findings are from an observational cohort study including 774 adult patients with PsA who started their first b/tsDMARD.
Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.
Source: Vallejo-Yague E et al. Minimal disease activity and remission in patients with psoriatic arthritis with elevated body mass index: An observational cohort study in the Swiss Clinical Quality Management cohort. BMJ Open. 2022;12(9):e061474 (Sep 17). Doi: 10.1136/bmjopen-2022-061474